Literature DB >> 6727121

No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome.

Y Ji-Yun, T Melvin, R Sibley, A F Michael.   

Abstract

To define the relationship of mesangial IgM to various morphologic categories of idiopathic nephrotic syndrome (INS), an analysis of 100 patients was carried out in which five morphologic subgroups were evaluated: group 1, minimal glomerular change (38 patients); group 2, minimal change with focal global sclerosis (18 patients); group 3, focal segmental glomerulosclerosis ( FSG ) (23 patients); group 4, mesangial proliferation (12 patients); group 5, focal segmental glomerulosclerosis with mesangial proliferation (9 patients). Immunohistochemical studies failed to demonstrate any differences between these five groups. The intensities of immunofluorescence and the percentage of tissue samples demonstrating IgM and/or C3 in the glomerular mesangium and subendothelial regions were similar. In addition, the presence or intensity of mesangial IgM did not predict the patients' current status or responsiveness to steroid therapy. Morphologic transitions were observed in patients who had more than one biopsy: one of five in group 2 and two of eight in group 3 developed mesangial proliferation; and nine of ten patients with mesangial proliferation in the first biopsy continued to show this finding in the second. In general, a complete response to steroid therapy and a favorable outcome is less likely in patients with this morphologic abnormality. In nine of the 27 repeat biopsies, there was lack of agreement between the first and second tissue samples with respect to the presence or absence of mesangial IgM. Although mesangial proliferation is a consistent feature of the morphology of certain patients with INS, these studies do not support a unique association with mesangial IgM.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727121     DOI: 10.1038/ki.1984.14

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Is cyclophosphamide effective in patients with IgM-positive minimal change disease?

Authors:  Pavel Geier; Amani Roushdi; Sylva Skálová; Jennifer Vethamuthu; Gabrielle Weiler; Janusz Feber
Journal:  Pediatr Nephrol       Date:  2012-06-24       Impact factor: 3.714

2.  IgM nephropathy; time to act.

Authors:  Muhammed Mubarak
Journal:  J Nephropathol       Date:  2014-01-01

Review 3.  Management of nephrotic syndrome in childhood.

Authors:  T Melvin; W Bennett
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

4.  Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome.

Authors:  Sarah J Swartz; Karen W Eldin; M John Hicks; Daniel I Feig
Journal:  Pediatr Nephrol       Date:  2009-02-14       Impact factor: 3.714

5.  Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular "immune deposits".

Authors:  R Habib; E Girardin; M F Gagnadoux; N Hinglais; M Levy; M Broyer
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

6.  IgM contributes to glomerular injury in FSGS.

Authors:  Derek Strassheim; Brandon Renner; Sarah Panzer; Richard Fuquay; Liudmila Kulik; Danica Ljubanović; V Michael Holers; Joshua M Thurman
Journal:  J Am Soc Nephrol       Date:  2013-02-07       Impact factor: 10.121

7.  Circulating heavy IgM in IgM nephropathy.

Authors:  S O Disciullo; J G Abuelo; K Moalli; J C Pezzullo
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

Review 8.  IgM nephropathy; can we still ignore it.

Authors:  Aruna Vanikar
Journal:  J Nephropathol       Date:  2013-04-01

Review 9.  IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?

Authors:  R Brugnano; R Del Sordo; C Covarelli; E Gnappi; S Pasquali
Journal:  J Nephrol       Date:  2016-02-03       Impact factor: 3.902

10.  The natural history of immunoglobulin M nephropathy in adults.

Authors:  Thomas M Connor; Valeria Aiello; Megan Griffith; Thomas Cairns; Candice A Roufosse; H Terence Cook; Charles D Pusey
Journal:  Nephrol Dial Transplant       Date:  2017-05-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.